School of Pharmacy, Catholic University of Health and Allied Sciences, Mwanza, United Republic of Tanzania
Department of Research, Haydom Lutheran Hospital, Mbulu, Manyara, United Republic of Tanzania.
BMJ Open. 2022 Apr 7;12(4):e059030. doi: 10.1136/bmjopen-2021-059030.
To examine the association between antenatal corticosteroids (ACS) use and perinatal mortality in singletons and twins delivered before 35 weeks of gestation.
Secondary analysis of data from an observational prospective chart review study that investigated if exposure to ACS was associated with lower rates of perinatal mortality in preterm infants.
This study was conducted in four hospitals located in Mwanza region, Tanzania.
The study population included all preterm singletons and twins delivered at these hospitals between 24 weeks 0 days and 34 weeks 6 days of gestation from July 2019 to February 2020.
The primary outcome was perinatal mortality; the secondary outcome was respiratory distress syndrome (RDS).
The study included 844 singletons and 210 twin infants. Three hundred and fourteen singletons (37.2%) and 52 twins (24.8%) were exposed to at least one dose of ACS. Adjusted multivariate analyses revealed that among singletons' exposure to ACS was significantly associated with a lower likelihood of perinatal mortality, adjusted relative risk (aRR) 0.30 (95% CI 0.22 to 0.40) and RDS, aRR 0.92 (95% CI 0.87 to 0.97). In twin infants, exposure to ACS was associated with a reduced risk of RDS only, aRR 0.87 (95% CI 0.78 to 0.98).
The use of ACS between 24 weeks 0 days and 34 weeks 6 days of gestation in both singletons and twins in low-resource settings is associated with positive infant outcomes. No adverse effects were noted. Further research that examines the benefits of ACS for twin infants is needed.
探讨产前皮质类固醇(ACS)在 35 周前分娩的单胎和双胎中的使用与围产儿死亡率之间的关系。
对一项观察性前瞻性图表回顾研究的数据进行二次分析,该研究调查 ACS 暴露是否与早产儿围产儿死亡率降低有关。
这项研究在坦桑尼亚姆万扎地区的四家医院进行。
研究人群包括 2019 年 7 月至 2020 年 2 月在这些医院 24 周零 0 天至 34 周零 6 天之间分娩的所有早产单胎和双胎。
主要结局是围产儿死亡率;次要结局是呼吸窘迫综合征(RDS)。
研究纳入了 844 例单胎和 210 例双胎婴儿。314 例单胎(37.2%)和 52 例双胎(24.8%)接受了至少一剂 ACS。调整后的多变量分析显示,单胎 ACS 暴露与围产儿死亡率显著降低相关,调整后的相对风险(aRR)为 0.30(95%CI 0.22 至 0.40)和 RDS,aRR 为 0.92(95%CI 0.87 至 0.97)。在双胎婴儿中,ACS 暴露仅与 RDS 风险降低相关,aRR 为 0.87(95%CI 0.78 至 0.98)。
在资源匮乏的环境中,24 周零 0 天至 34 周零 6 天之间对单胎和双胎使用 ACS 与婴儿结局呈正相关。未观察到不良反应。需要进一步研究 ACS 对双胎婴儿的益处。